Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL303618 | 0.89 | HPRT1 (0.50) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL129188 | 0.88 | CYP1A2 (0.54) | TDP1CYP1A2CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL303467 | 0.87 | HPRT1 (0.48) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL303912 | 0.86 | HPRT1 (0.47) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL304267 | 0.86 | HPRT1 (0.47) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL302632 | 0.86 | HPRT1 (0.47) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL304226 | 0.86 | HPRT1 (0.47) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL303588 | 0.86 | HPRT1 (0.47) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL303031 | 0.86 | HPRT1 (0.47) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 | |
| SCHEMBL303188 | 0.86 | HPRT1 (0.47) | HPRT1ALDH1A1HSD17B10TDP1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966456-B1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2003-04-02 | — | — | EP | claimed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | claimed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | claimed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | claimed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | claimed |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-07-18 | — | — | US | disclosed |
| EP-4375280-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371985-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-22 | — | — | EP | disclosed |
| EP-4371984-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-22 | — | — | EP | disclosed |
| CN-117836290-A | Synthesis method of bilirubin | 株式会社毕丽斯 | 2024-04-05 | — | — | CN | disclosed |
| CN-117813301-A | Synthesis method of bilirubin | 株式会社毕丽斯 | 2024-04-02 | — | — | CN | disclosed |
| CN-117551696-A | Composition for transfecting nucleic acid molecules into cells comprising triazole compounds grafted onto cationic polymers and uses thereof | 宝利普拉斯生物转染公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-1092730-A1 | PROCESS FOR PRODUCING OLEFIN POLYMER AND OLEFIN POLYMER | Mitsui Chemicals, Inc. (JP) | 2001-04-18 | — | — | EP | disclosed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | disclosed |
| US-6004897-A | TRANSITION METAL INDENE-FLUORINE COMPLEX COORDINATION CATALYST WITH ORGANOALUMINUM AND ALUMOXANE COMPOUNDS | MITSUI CHEMICALS, INC. (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0962437-A1 | Linear triene and copolymer thereof | Mitsui Chemicals, Inc. (JP) | 1999-12-08 | — | — | EP | disclosed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | disclosed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0754698-A2 | An olefin polymerization catalyst and a process for preparing olefin polymer | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | CYP7A1, UGT1A3, UGT1A1 | HPRT1 441/4885ALDH1A1 225/4885HSD17B10 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.